EDSA Edesa Biotech, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1540159 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-138.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-122.9%
ROA-102.5%
ROIC (approx.)-9,500.4%
Asset turnover—
Leverage & solvency
Liabilities / assets30.7%
Debt / equity0.00x
Current ratio2.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-37.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY20212021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | $0 |
| Cost of revenue | — | — | — | — | $0 |
| Gross profit | — | — | — | — | $0 |
| R&D expense | $3.67M | $2.88M | $4.79M | $13.34M | $17.95M |
| SG&A expense | $4.24M | $4.13M | $4.43M | $5.04M | $5.73M |
| Operating income | -$7.91M | -$7.01M | -$9.22M | -$18.37M | -$23.68M |
| Pretax income | -$7.18M | -$6.17M | -$8.37M | -$17.55M | -$13.34M |
| Income tax | $800 | $800 | $800 | $800 | $800 |
| Net income | -$7.19M | -$6.17M | -$8.37M | -$17.55M | -$13.34M |
| EBITDA | -$7.79M | -$6.83M | -$9.04M | -$18.25M | -$23.56M |
| EPS (basic) | -1.27 | -1.93 | -2.93 | — | -1.10 |
| EPS (diluted) | — | — | — | — | -1.10 |
| Weighted avg. shares (diluted) | — | — | — | — | 12.08M |
| Balance sheet | |||||
| Cash & equivalents | $10.79M | $1.04M | $5.36M | $7.09M | $7.84M |
| Receivables | — | — | — | — | $3.30M |
| Current assets | $11.51M | $1.68M | $6.44M | $9.09M | $12.09M |
| PP&E, net | — | $0 | $8,702 | $12,694 | $14,989 |
| Intangibles | $1.98M | $2.08M | $2.18M | $2.28M | $2.38M |
| Total assets | $13.53M | $3.81M | $8.89M | $11.58M | $14.58M |
| Current liabilities | $1.08M | $1.83M | $1.82M | $2.14M | $1.46M |
| Total liabilities | $1.08M | $1.83M | $1.84M | $2.18M | $1.53M |
| Shareholders' equity | $12.45M | $1.98M | $7.05M | $9.39M | $13.06M |
| Shares outstanding | 7.14M | 3.25M | 3.08M | 2.38M | 13.30M |
| Cash flow statement | |||||
| Operating cash flow | -$7.32M | -$4.89M | -$6.64M | -$12.28M | -$13.66M |
| Capital expenditure | — | — | $0 | $5,656 | $6,146 |
| Free cash flow | — | — | -$6.64M | -$12.28M | -$13.67M |
| Investing cash flow | — | — | $0 | -$5,656 | -$6,146 |
| Financing cash flow | $17.03M | $592,031 | $4.83M | $11.63M | $14.17M |
| Depreciation & amortization | $119,273 | $186,049 | $183,471 | $118,188 | $118,788 |
| Stock-based compensation | $729,642 | $537,492 | $1.25M | $2.26M | $3.20M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.